# Read the finding with its limits attached.

Here's the reading behind the guide. Some papers follow hormone signals, others measure outcomes in people. The FDA sources explain safety and approval. A source is most useful when we keep its question beside its finding.

[Pure Fusion Peptides](/) / References

## Ipamorelin and the difference between signal and outcome

- [Ipamorelin in early cell and animal tests](https://pubmed.ncbi.nlm.nih.gov/9849822/)

  Raun and colleagues, 1998. The experiments found a selective growth-hormone response. They did not test sleep or everyday recovery in people.

- [The human ipamorelin hormone study](https://pubmed.ncbi.nlm.nih.gov/10496658/)

  Gobburu and colleagues, 1999. Healthy men received intravenous ipamorelin. The study followed drug levels and a short growth-hormone burst, rather than sleep or recovery.

- [Ipamorelin after bowel surgery](https://pubmed.ncbi.nlm.nih.gov/25331030/)

  Beck and colleagues, 2014. The trial missed its main goal of showing earlier meal tolerance. That result matters, even when the idea behind a treatment sounds plausible.

- [FDA's review of ipamorelin](https://www.fda.gov/media/182088/download)

  FDA, 2024. This review describes the human studies and gaps in basic safety testing. It also raises concerns about possible immune reactions to injected preparations.

## CJC-1295 and the exact form tested

- [The long-acting CJC-1295 human study](https://pubmed.ncbi.nlm.nih.gov/16352683/)

  Teichman and colleagues, 2006. Growth hormone and IGF-1 stayed raised for days. That finding belongs to the long-acting form tested, rather than any proposed mixture.

- [Growth-hormone bursts during CJC-1295 stimulation](https://pubmed.ncbi.nlm.nih.gov/17018654/)

  Ionescu and Frohman, 2006. Hormone bursts continued during longer stimulation. This tells us about the pattern of release, rather than the benefit of adding another peptide.

- [FDA's review of CJC-1295 forms and risks](https://www.fda.gov/media/183819/download)

  FDA, 2024. The review distinguishes related forms and flags confusing names. It discusses adverse reactions, possible immune responses and unknown long-term safety.

## Tirzepatide, BPC-157 and the safety context

- [Tirzepatide in a weight-management trial](https://pubmed.ncbi.nlm.nih.gov/35658024/)

  Jastreboff and colleagues, 2022. Adults taking tirzepatide lost more weight on average than those taking placebo. The trial did not test adding the other peptides discussed here.

- [Tirzepatide weight-management prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)

  The U.S. label describes the approved product, its uses, warnings and interactions. It supplies safety context that an average trial result cannot give on its own.

- [BPC-157 and musculoskeletal healing](https://pubmed.ncbi.nlm.nih.gov/40789979/)

  McGuire and colleagues, 2025. This review describes extremely limited human evidence alongside the animal research. It calls for stronger studies before treating repair claims as established.

- [The two-person BPC-157 safety pilot](https://pubmed.ncbi.nlm.nih.gov/40131143/)

  Lee and Burgess, 2025. This intravenous pilot reported no adverse events in two adults. It did not test injury healing and cannot establish long-term safety.

- [BPC-157 and new blood-vessel growth](https://pubmed.ncbi.nlm.nih.gov/27847966/)

  Hsieh and colleagues, 2017. Cell and animal experiments explored effects on vessel growth. Those findings help explain the repair idea without proving that people heal faster.

- [FDA's bulk-substance safety page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

  The page current as of April 22, 2026 separates Category 2 from withdrawn nominations. The requests were taken back, but FDA still records the safety worries.

- [FDA's explanation of compounded-drug risks](https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs)

  Compounded medicines have no FDA approval, as this FDA explanation makes clear. An approved active ingredient doesn't make a different preparation or an added ingredient approved.

## Read for the result you care about.

Who received what, what changed, and was the proposed pairing actually tested?

We pull peptide pairings apart in this reading guide; we're not a clinic, pharmacy or seller.

[Combinations](/compare) · [References](/references) · [Questions](/faq) · [About](/about) · [Contact](/contact)

© 2026 Pure Fusion Peptides

An owner’s guide to combination claims.

[The argument](/#argument) · [The compounds](/#compounds) · [Our approach](/about)